ArticleslgStudy

chemistry

WJ0679

WJ0679 is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand WJ0679 rather than just read about it. In short: WJ0679 is a small-molecule oxytocin receptor agonist and vasopressin receptor antagonist. It acts specifically as a very weak partial agonist of the oxytocin receptor (Ki = 422 nM; EC50Tooltip half-maximal effective concentration = 406 nM; EmaxTooltip maximal efficacy = 13%) and as an antagonist of the vasopressin V1A receptor (Ki = 105 nM; IC50Tooltip half-maximal inhibitory concentration = 2,203 nM), whereas no da…

WJ0679 — main illustration
WJ0679 — illustration

Key takeaways

  • WJ0679 belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect WJ0679 to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of WJ0679 from memory before moving on to harder problems.

Reference excerpt

WJ0679 is a small-molecule oxytocin receptor agonist and vasopressin receptor antagonist. It acts specifically as a very weak partial agonist of the oxytocin receptor (Ki = 422 nM; EC50Tooltip half-maximal effective concentration = 406 nM; EmaxTooltip maximal efficacy = 13%) and as an antagonist of the vasopressin V1A receptor (Ki = 105 nM; IC50Tooltip half-maximal inhibitory concentration = 2,203 nM), whereas no data were reported for the vasopressin V2 receptor. Despite its low activational efficacy at the oxytocin receptor, WJ0679 induces prosocial effects, including increased time spent in close physical contact and increased active social investigation, in rodents. The chemical synthesis of WJ0679 has been described. Along with its close analogue CA7, WJ0679 has the smallest chemical structure known for an oxytocin receptor agonist, with WJ0679 having about 60% of the molecular weight of LIT-001 and both WJ0679 and CA7 lacking LIT-001's tail component. Many analogues of WJ0679 and CA7 have been described. WJ0679 was first described in the scientific literature by a group including Michael Kassiou, Michael Bowen, Iain McGregor, and others at the University of Sydney in 2018. This group has founded a startup pharmaceutical company called Kinoxis Therapeutics and is developing small-molecule oxytocin-related drugs like KNX-100 and the KNX-200 series for potential medical use as of the 2020s.

See also Oxytocin receptor agonist CA7 and KNX-100

References

Illustrations

WJ0679 illustration

Worked examples

Example 1 — a first encounter with WJ0679

Start with the simplest possible case. Write down what WJ0679 claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to WJ0679 before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about WJ0679 ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of WJ0679

In research
WJ0679 appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses WJ0679 in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
WJ0679 is common in secondary-school and first-year university syllabi. It links to neighbouring topics 3-Fluorophenyl compounds, Benzodiazepines, Carboxamides, so understanding it makes those chapters shorter.
In everyday life
Look for WJ0679 outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study WJ0679 in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what WJ0679 means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain WJ0679 out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is WJ0679 in simple terms?

WJ0679 is a small-molecule oxytocin receptor agonist and vasopressin receptor antagonist. It acts specifically as a very weak partial agonist of the oxytocin receptor (Ki = 422 nM; EC50Tooltip half-maximal effective concentration = 406 nM; EmaxTooltip maximal efficacy = 13%) and as an antagonist of…

Why does WJ0679 matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study WJ0679?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on WJ0679.

Tags

  • 3-Fluorophenyl compounds
  • Benzodiazepines
  • Carboxamides
  • Drugs not assigned an ATC code
  • Ketones
  • Methyl compounds
  • Oxytocin receptor agonists
  • Pyrazolobenzodiazepines
  • Vasopressin receptor antagonists

Keep exploring